VYEPTI

This brand name is authorized in United States. It is also authorized in Austria, Estonia, France, Israel, Lithuania, Poland, Romania, Spain.

Active ingredients

The drug VYEPTI contains one active pharmaceutical ingredient (API):

1	Eptinezumab UNII 8202AY8I7H - EPTINEZUMAB
	Eptinezumab is a recombinant humanized immunoglobulin G1 (IgG1) antibody that binds to α- and β-forms of human calcitonin gene-related peptide (CGRP) ligand with low picomolar affinity. Eptinezumab prevents the activation of the CGRP receptors and hence the downstream cascade of physiological events linked to initiation of migraine attacks.
	Read more about Eptinezumab

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
VYEPTI Concentrate for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)
VYEPTI Solution for injection	MPI, US: SPL/PLR	FDA, National Drug Code (US)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
N02CD05		N Nervous system → N02 Analgesics → N02C Antimigraine preparations → N02CD Calcitonin gene-related peptide (CGRP) antagonists
Discover more medicines within N02CD05

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	1874358
ES	Centro de información online de medicamentos de la AEMPS	1211599001
FR	Base de données publique des médicaments	64842858
IL	מִשְׂרַד הַבְּרִיאוּת	9347
LT	Valstybinė vaistų kontrolės tarnyba	1094046, 1096010
PL	Rejestru Produktów Leczniczych	100465456
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69462001, W69462002
US	FDA, National Drug Code	67386-130